Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Price ‘Negotiation’ Would Have Stymied Verzenio Advance In Early Cancer – Lilly’s Ricks

Executive Summary

‘It takes longer than nine years’ to profit from small molecule drug R&D, company CEO maintains in arguments against the negotiation process, and its timelines, in the Senate drug pricing reform legislation.

You may also be interested in...



As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan

With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.

Don’t Look Up? Congress Can’t Ignore Risk To Small Molecule Drugs In Pricing Bill, Investors Warn

A budget-neutral fix that would extend the time before small molecule drugs are subject negotiations but increase the minimum discounts for the products is floated as the pricing legislation moves toward a Senate floor vote.

Don’t Look Up? Investors Call For Tweaks To Small Molecule Provisions In US Pricing Bill

Investors and pharma stakeholders scramble to extend the time period before small molecule drugs are subject to government mandated discounts as Senate drug pricing legislation moves toward a floor vote.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS146779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel